The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Industry Update: Interim 503A and 503B Bulks Lists New Revisions